Investor Day and July Meetings Recap
Hi, I’m Alex Schwartz and I recently joined Esperion as Head of Investor Relations. Prior to joining Esperion, I was… more
Posted by mlowe@esperion.comPOSITIVELY PRECISE.
We’re developing targeted therapies to lower LDL-cholesterol for patients not adequately treated with current lipid-modifying therapies.
Learn More
Pipeline
Esperion is a late-stage pharmaceutical company focused on developing and commercializing non-statin, convenient, complementary, consistent, once-daily, oral, LDL-C lowering therapies for the treatment of patients with hypercholesterolemia.
learn moreRECENT PRESS RELEASES
- Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Bempedoic Acid / Ezetimibe Combination Pill Study
- Esperion Announces Late-Breaking Oral Presentation of Final Results of Phase 3 Long-Term Safety Study of Bempedoic Acid at the European Society of Cardiology Congress
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Latest Tweets
moreHEARTS & MINDS BLOG
A Closer Look – June 2018
As we approach the halfway point in 2018, our Lipid Management Team remains confident and encouraged by the consistently positive… more
Posted by mlowe@esperion.comKey Insights from March 2018 ACC: CLEAR Outcomes Looking Even CLEARer After ODYSSEY – Updated ICER Cost-Effectiveness Analysis A Win for Patients and for the Bempedoic Acid Franchise
Our Lipid Management Team attended the 67th Annual Scientific Session of the American College of Cardiology (ACC) in Orlando this… more
Posted by mlowe@esperion.com